Table of Contents
Chapter 1. Global Motion Sickness Drugs Market Executive Summary
1.1. Global Motion Sickness Drugs Market Size & Forecast (2022- 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Product Type
1.3.2. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Motion Sickness Drugs Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer's Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Motion Sickness Drugs Market Dynamics
3.1. Market Drivers
3.1.1. Availability of Over-the-Counter (OTC) Drugs
3.1.2. Increase in Travel and Tourism
3.2. Market Challenges
3.2.1. Emergence of Nonpharmacological Treatments
3.2.2. Introduction of Generic Alternatives
3.3. Market Opportunities
3.3.1. Focus on Product Innovation
3.3.2. Increasing Online Sales Channels
Chapter 4. Global Motion Sickness Drugs Market Industry Analysis
4.1. Porter's 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter's 5 Force Model
4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Motion Sickness Drugs Market Size & Forecasts by Product Type 2022-2032
5.1. Segment Dashboard
5.2. Global Motion Sickness Drugs Market: Product Type Revenue Trend Analysis, 2022 & 2032 (USD Million)
5.2.1. Antihistamines
5.2.2. Anticholinergics
Chapter 6. Global Motion Sickness Drugs Market Size & Forecasts by Distribution Channel 2022-2032
6.1. Segment Dashboard
6.2. Global Motion Sickness Drugs Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Million)
6.2.1. Offline
6.2.2. Online
Chapter 7. Global Motion Sickness Drugs Market Size & Forecasts by Region 2022-2032
7.1. North America Motion Sickness Drugs Market
7.1.1. U.S. Motion Sickness Drugs Market
7.1.1.1. Product Type breakdown size & forecasts, 2022-2032
7.1.1.2. Distribution Channel breakdown size & forecasts, 2022-2032
7.1.2. Canada Motion Sickness Drugs Market
7.2. Europe Motion Sickness Drugs Market
7.2.1. U.K. Motion Sickness Drugs Market
7.2.2. Germany Motion Sickness Drugs Market
7.2.3. France Motion Sickness Drugs Market
7.2.4. Spain Motion Sickness Drugs Market
7.2.5. Italy Motion Sickness Drugs Market
7.2.6. Rest of Europe Motion Sickness Drugs Market
7.3. Asia-Pacific Motion Sickness Drugs Market
7.3.1. China Motion Sickness Drugs Market
7.3.2. India Motion Sickness Drugs Market
7.3.3. Japan Motion Sickness Drugs Market
7.3.4. Australia Motion Sickness Drugs Market
7.3.5. South Korea Motion Sickness Drugs Market
7.3.6. Rest of Asia Pacific Motion Sickness Drugs Market
7.4. Latin America Motion Sickness Drugs Market
7.4.1. Brazil Motion Sickness Drugs Market
7.4.2. Mexico Motion Sickness Drugs Market
7.4.3. Rest of Latin America Motion Sickness Drugs Market
7.5. Middle East & Africa Motion Sickness Drugs Market
7.5.1. Saudi Arabia Motion Sickness Drugs Market
7.5.2. South Africa Motion Sickness Drugs Market
7.5.3. Rest of Middle East & Africa Motion Sickness Drugs Market
Chapter 8. Competitive Intelligence
8.1. Key Company SWOT Analysis
8.2. Top Market Strategies
8.3. Company Profiles
8.3.1. Abbott Laboratories
8.3.1.1. Key Information
8.3.1.2. Overview
8.3.1.3. Financial (Subject to Data Availability)
8.3.1.4. Product Summary
8.3.1.5. Market Strategies
8.3.2. Baxter International Inc.
8.3.3. CVS Health Corp.
8.3.4. GlaxoSmithKline Plc
8.3.5. Novartis AG
8.3.6. Sun Pharmaceutical Industries Ltd.
8.3.7. Teva Pharmaceutical Industries Ltd.
8.3.8. Lupin Ltd.
8.3.9. Merck KGaA
8.3.10. Pfizer Inc.
8.3.11. Amneal Pharmaceuticals Inc.
8.3.12. Hylands
8.3.13. Myungmoon Pharm Co. Ltd.
8.3.14. Zydus Lifesciences Ltd.
8.3.15. Viatris Inc.
Chapter 9. Research Process
9.1. Research Process
9.1.1. Data Mining
9.1.2. Analysis
9.1.3. Market Estimation
9.1.4. Validation
9.1.5. Publishing
9.2. Research Attributes